1. Home
  2. EPAM vs ACAD Comparison

EPAM vs ACAD Comparison

Compare EPAM & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo EPAM Systems Inc.

EPAM

EPAM Systems Inc.

HOLD

Current Price

$112.93

Market Cap

5.1B

Sector

Technology

ML Signal

HOLD

ACAD

ACADIA Pharmaceuticals Inc.

N/A

Current Price

$29.72

Market Cap

4.3B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
EPAM
ACAD
Founded
1993
1993
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.1B
4.3B
IPO Year
2011
2000

Fundamental Metrics

Financial Performance
Metric
EPAM
ACAD
Price
$112.93
$29.72
Analyst Decision
Buy
Buy
Analyst Count
14
22
Target Price
$196.21
$30.55
AVG Volume (30 Days)
1.4M
1.7M
Earning Date
05-07-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
69.12
EPS
3.49
0.20
Revenue
$1,450,448,000.00
$726,437,000.00
Revenue This Year
$8.30
$18.80
Revenue Next Year
$7.17
$11.70
P/E Ratio
$32.31
$148.65
Revenue Growth
25.02
40.45
52 Week Low
$73.06
$19.69
52 Week High
$222.53
$30.96

Technical Indicators

Market Signals
Indicator
EPAM
ACAD
Relative Strength Index (RSI) 64.90 60.20
Support Level $84.19 $25.00
Resistance Level $135.00 $30.96
Average True Range (ATR) 4.42 0.88
MACD 0.73 -0.07
Stochastic Oscillator 91.33 59.15

Price Performance

Historical Comparison
EPAM
ACAD

About EPAM EPAM Systems Inc.

EPAM Systems is a global IT services firm with a focus on platform engineering, software development, and consulting services. The company used to host large engineer bases in Ukraine, Belarus, and Russia, but it now delivers from various locations across different continents. EPAM's largest market is North America, which represents approximately 60% of revenue.

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.

Share on Social Networks: